Literature DB >> 24145402

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Rajesh P Ringe1, Rogier W Sanders, Anila Yasmeen, Helen J Kim, Jeong Hyun Lee, Albert Cupo, Jacob Korzun, Ronald Derking, Thijs van Montfort, Jean-Philippe Julien, Ian A Wilson, Per Johan Klasse, Andrew B Ward, John P Moore.   

Abstract

We compare the antigenicity and conformation of soluble, cleaved vs. uncleaved envelope glycoprotein (Env gp)140 trimers from the subtype A HIV type 1 (HIV-1) strain BG505. The impact of gp120-gp41 cleavage on trimer structure, in the presence or absence of trimer-stabilizing modifications (i.e., a gp120-gp41 disulfide bond and an I559P gp41 change, together designated SOSIP), was assessed. Without SOSIP changes, cleaved trimers disintegrate into their gp120 and gp41-ectodomain (gp41ECTO) components; when only the disulfide bond is present, they dissociate into gp140 monomers. Uncleaved gp140s remain trimeric whether SOSIP substitutions are present or not. However, negative-stain electron microscopy reveals that only cleaved trimers form homogeneous structures resembling native Env spikes on virus particles. In contrast, uncleaved trimers are highly heterogeneous, adopting a variety of irregular shapes, many of which appear to be gp120 subunits dangling from a central core that is presumably a trimeric form of gp41ECTO. Antigenicity studies with neutralizing and nonneutralizing antibodies are consistent with the EM images; cleaved, SOSIP-stabilized trimers express quaternary structure-dependent epitopes, whereas uncleaved trimers expose nonneutralizing gp120 and gp41ECTO epitopes that are occluded on cleaved trimers. These findings have adverse implications for using soluble, uncleaved trimers for structural studies, and the rationale for testing uncleaved trimers as vaccine candidates also needs to be reevaluated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145402      PMCID: PMC3831437          DOI: 10.1073/pnas.1314351110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity.

Authors:  Zhihai Si; Ngoc Phan; Enko Kiprilov; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2003-03       Impact factor: 2.205

2.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

4.  A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Authors:  Paul Spearman; Michelle A Lally; Marnie Elizaga; David Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Stephen C De Rosa; Alicia Sato; Yunda Huang; Sharon E Frey; Paul Sato; John Donnelly; Susan Barnett; Lawrence J Corey
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

5.  Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Authors:  Tommy Tong; Keiko Osawa; James E Robinson; Ema T Crooks; James M Binley
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

6.  An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Authors:  Guido Ferrari; Justin Pollara; Daniel Kozink; Tiara Harms; Mark Drinker; Stephanie Freel; M Anthony Moody; S Munir Alam; Georgia D Tomaras; Christina Ochsenbauer; John C Kappes; George M Shaw; James A Hoxie; James E Robinson; Barton F Haynes
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

Review 8.  HIV-1 neutralization: mechanisms and relevance to vaccine design.

Authors:  Michael B Zwick; Dennis R Burton
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

9.  Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Authors:  Jean-Philippe Julien; Devin Sok; Reza Khayat; Jeong Hyun Lee; Katie J Doores; Laura M Walker; Alejandra Ramos; Devan C Diwanji; Robert Pejchal; Albert Cupo; Umesh Katpally; Rafael S Depetris; Robyn L Stanfield; Ryan McBride; Andre J Marozsan; James C Paulson; Rogier W Sanders; John P Moore; Dennis R Burton; Pascal Poignard; Andrew B Ward; Ian A Wilson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  128 in total

1.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

4.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

5.  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

Review 6.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

7.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Authors:  Dmitry Lyumkis; Jean-Philippe Julien; Natalia de Val; Albert Cupo; Clinton S Potter; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Bridget Carragher; Ian A Wilson; Andrew B Ward
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

8.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Authors:  Claudia Blattner; Jeong Hyun Lee; Kwinten Sliepen; Ronald Derking; Emilia Falkowska; Alba Torrents de la Peña; Albert Cupo; Jean-Philippe Julien; Marit van Gils; Peter S Lee; Wenjie Peng; James C Paulson; Pascal Poignard; Dennis R Burton; John P Moore; Rogier W Sanders; Ian A Wilson; Andrew B Ward
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

Review 9.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

Review 10.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.